甲状腺激素治疗强度与美国退伍军人心血管死亡的相关性
这项回顾性队列研究纳入2004年1月1日至2017年12月31日接受甲状腺激素治疗的705 307名退伍军人,中位随访4年(IQR 2-9年),分析血清促甲状腺激素和游离甲状腺素(FT4)水平与心血管死亡的关系。结果显示,与甲状腺功能正常者相比,外源性甲状腺功能亢进(促甲状腺激素<0.1 mIU/L:AHR 1.39,95%CI 1.32-1.47;FT4>1.9 ng/dL:AHR 1.29,95%CI 1.20-1.40)和外源性甲状腺功能减退(促甲状腺激素>20 mIU/L:AHR 2.67,95%CI 2.55-2.80;FT4<0.7 ng/dL:AHR 1.56,95%CI 1.50-1.63)均与心血管死亡风险升高相关。作者认为,维持甲状腺功能正常可能降低接受甲状腺激素治疗患者的心血管风险和死亡。
要点
- 接受甲状腺激素治疗的退伍军人中,外源性甲状腺功能亢进(促甲状腺激素<0.1 mIU/L)与心血管死亡风险升高相关(AHR 1.39,95%CI 1.32-1.47)。
- 外源性甲状腺功能减退(促甲状腺激素>20 mIU/L)也与心血管死亡风险升高相关(AHR 2.67,95%CI 2.55-2.80)。
- FT4>1.9 ng/dL时心血管死亡风险升高(AHR 1.29,95%CI 1.20-1.40),FT4<0.7 ng/dL时也升高(AHR 1.56,95%CI 1.50-1.63)。
- 总队列705 307人中,75 963人(10.8%)死于心血管原因,中位随访4年(IQR 2-9年)。
- 作者认为,维持甲状腺功能正常可能降低接受甲状腺激素治疗患者的心血管风险和死亡。
适用人群与场景
- 2004年1月1日至2017年12月31日期间在退伍军人健康管理局企业数据仓库接受甲状腺激素治疗的705 307名成人。
- 分析队列一:701 929名18岁及以上成人,在治疗开始至死亡或研究结束期间至少有2次促甲状腺激素测量。
- 分析队列二:373 981名患者,至少有2次FT4测量。
诊断标准与关键阈值
- 甲状腺功能正常:促甲状腺激素0.5-5.5 mIU/L;FT4 0.7-1.9 ng/dL。
- 外源性甲状腺功能亢进:促甲状腺激素<0.5 mIU/L;FT4>1.9 ng/dL。
- 外源性甲状腺功能减退:促甲状腺激素>5.5 mIU/L;FT4<0.7 ng/dL。
研究设计与关键结果
- 研究类型:回顾性队列研究;样本量705 307人;人群为接受甲状腺激素治疗的退伍军人;中位随访4年(IQR 2-9年)。
- 总队列中625 444人(88.7%)为男性,中位年龄67岁(IQR 57-78岁;范围18-110岁)。
- 75 963人(10.8%)死于心血管原因。
- 调整年龄、性别、传统心血管危险因素(如高血压、吸烟、既往心血管疾病或心律失常)后,外源性甲状腺功能亢进(促甲状腺激素<0.1 mIU/L:AHR 1.39,95%CI 1.32-1.47;FT4>1.9 ng/dL:AHR 1.29,95%CI 1.20-1.40)与心血管死亡风险升高相关。
- 外源性甲状腺功能减退(促甲状腺激素>20 mIU/L:AHR 2.67,95%CI 2.55-2.80;FT4<0.7 ng/dL:AHR 1.56,95%CI 1.50-1.63)与心血管死亡风险升高相关。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,维持甲状腺功能正常可能降低接受甲状腺激素治疗患者的心血管风险和死亡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Cardiovascular disease is the leading cause of death in the United States. Synthetic thyroid hormones are among the 3 most commonly prescribed medications, yet studies evaluating the association between the intensity of thyroid hormone treatment and cardiovascular mortality are scarce.
OBJECTIVE: To evaluate the association between thyroid hormone treatment intensity and cardiovascular mortality.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data on 705 307 adults who received thyroid hormone treatment from the Veterans Health Administration Corporate Data Warehouse between January 1, 2004, and December 31, 2017, with a median follow-up of 4 years (IQR, 2-9 years). Two cohorts were studied: 701 929 adults aged 18 years or older who initiated thyroid hormone treatment with at least 2 thyrotropin measurements between treatment initiation and either death or the end of the study period, and, separately, 373 981 patients with at least 2 free thyroxine (FT4) measurements. Data were merged with the National Death Index for mortality ascertainment and cause of death, and analysis was conducted from March 25 to September 2, 2020.
EXPOSURES: Time-varying serum thyrotropin and FT4 levels (euthyroidism: thyrotropin level, 0.5-5.5 mIU/L; FT4 level, 0.7-1.9 ng/dL; exogenous hyperthyroidism: thyrotropin level, <0.5 mIU/L; FT4 level, >1.9 ng/dL; exogenous hypothyroidism: thyrotropin level, >5.5 mIU/L; FT4 level, <0.7 ng/dL).
MAIN OUTCOMES AND MEASURES: Cardiovascular mortality (ie, death from cardiovascular causes, including myocardial infarction, heart failure, or stroke). Survival analyses were performed using Cox proportional hazards regression models using serum thyrotropin and FT4 levels as time-varying covariates.
RESULTS: Of the 705 307 patients in the study, 625 444 (88.7%) were men, and the median age was 67 years (IQR, 57-78 years; range, 18-110 years). Overall, 75 963 patients (10.8%) died of cardiovascular causes. After adjusting for age, sex, traditional cardiovascular risk factors (eg, hypertension, smoking, and previous cardiovascular disease or arrhythmia), patients with exogenous hyperthyroidism (eg, thyrotropin levels, <0.1 mIU/L: adjusted hazard ratio [AHR], 1.39; 95% CI, 1.32-1.47; FT4 levels, >1.9 ng/dL: AHR, 1.29; 95% CI, 1.20-1.40) and patients with exogenous hypothyroidism (eg, thyrotropin levels, >20 mIU/L: AHR, 2.67; 95% CI, 2.55-2.80; FT4 levels, <0.7 ng/dL: AHR, 1.56; 95% CI, 1.50-1.63) had increased risk of cardiovascular mortality compared with individuals with euthyroidism.
CONCLUSIONS AND RELEVANCE: This study suggests that both exogenous hyperthyroidism and exogenous hypothyroidism were associated with increased risk of cardiovascular mortality. These findings emphasize the importance of maintaining euthyroidism to decrease cardiovascular risk and death among patients receiving thyroid hormone treatment.
参考来源
- Evron JM, Hummel SL, Reyes-Gastelum D, et al. Association of Thyroid Hormone Treatment Intensity With Cardiovascular Mortality Among US Veterans. JAMA Netw Open. 2022. PMID: 35552725. doi:10.1001/jamanetworkopen.2022.11863
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。